Bafna Pharmaceuticals gets nod from Ghana for Omeran-20

Bafna Pharmaceuticals has received approval from Ghana to market Omeran-20 capsules used for the treatment of reflux oesophagitis among others.

May 03, 2013 / 16:44 IST

26 Aug, 2025 12:21

Volume

Todays L/H

Bafna Pharmaceuticals has received approval from Ghana to market Omeran-20 capsules used for the treatment of reflux oesophagitis among others. The city-based firm said the drug contains generic salt- Omeprazole and its international classification of diseases is Omeprazole.

"With this, Bafna now has 15 number of formulation approvals from Ghana Food and Drug Administration.", the company said in a BSE filing.

"This is a major milestone for Bafna Pharmaceuticals. It will strengthen our market in Ghana and helps us in penetrating in our target market segment," Bafna CMD Mahaveer Bafna said.

Shares of the company were trading at Rs 37.50 apiece, down by 0.27 percent over their previous close in the afternoon trade on the BSE.

first published: May 3, 2013 04:10 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

Al Edge Newsletter On Saturdays

Find the best of Al News in one place, specially curated for you every weekend.
MC Tech 3 Newsletter Daily-Weekdays

Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347